Literature DB >> 3978112

Chemical structure of carcinoma ganglioside antigens defined by monoclonal antibody C-50 and some allied gangliosides of human pancreatic adenocarcinoma.

J E Månsson, P Fredman, O Nilsson, L Lindholm, J Holmgren, L Svennerholm.   

Abstract

A hybridoma, C-50, obtained by fusion of mouse myeloma cells with spleen cells from a mouse immunized with cells from the colorectal carcinoma cell line COLO 205, produced antibodies that detected ganglioside antigen in human adenocarcinomas in many organs. The major ganglioside antigen fraction isolated from liver metastases of a pancreatic adenocarcinoma, behaving as a homogenous band on thin-layer chromatography, consisted of three different gangliosides. One of them, A (25%), had the same carbohydrate structure as the ganglioside antigen defined by monoclonal antibody 19-9, NeuAc alpha 2-3Gal beta 1-3(Fuc alpha 1-4)GlcNAc beta 1-3Gal beta 1-4Glc-Cer(Fuc-3'-isoLM1) Magnani, J.L., Nilsson, B., Brockhaus, M., Zopf, D., Steplewski, Z., Koprowski, H. and Ginsburg, V. (1982) J. Biol. Chem. 257, 14365-14369). The major ganglioside, B (60%), was the isomeric hexasaccharide ganglioside (NeuAc alpha 2-3Gal beta 1-4(Fuc alpha 1-3)GlcNAc beta 1-3-Gal beta 1-4Glc-Cer(Fuc-3'-LM1) and the third ganglioside, C, was 6'-LM1, NeuAc alpha 2-6Gal beta 1-4GlcNAc beta 1-3Gal beta 1-4Glc-Cer (15%). Ganglioside B, isolated from human kidney, did not react with the C-50 MAb. Based on this result and on studies of COLO 205 cell induced tumours where the ganglioside antigen fraction only consisted of A, it is suggested that the C-50 MAb defines an antigen determinant present in A.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978112     DOI: 10.1016/0005-2760(85)90182-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  Normal colon of Sprague-Dawley rats. An immunohistochemical study.

Authors:  J D Shetye; C A Rubio; H T Mellstedt
Journal:  Anat Embryol (Berl)       Date:  1992

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

3.  In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.

Authors:  P Fredman; C J Wikstrand; J E Månsson; G Reifenberger; S H Bigner; A Rasheed; L Svennerholm; D D Bigner
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

4.  A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer.

Authors:  K Satake; Y S Chung; H Yokomatsu; B Nakata; H Tanaka; T Sawada; H Nishiwaki; K Umeyama
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

5.  [Blood group antigen expression in papillary carcinoma of the thyroid gland. An immunohistochemical and clinical study of expression of Lewis, ABO and related antigens].

Authors:  A Larena; M Vierbuchen; S Schröder; A Larena-Avellaneda; I Hadshiew; R Fischer
Journal:  Langenbecks Arch Chir       Date:  1996

6.  Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.

Authors:  P Masson; B Pålsson; A Andren-Sandberg
Journal:  Int J Pancreatol       Date:  1991-05

7.  A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer.

Authors:  B E Persson; E Ståhle; L Påhlman; B Glimelius; O Nilsson; L Lindholm; B Norrgård-Pedersen; J Holmgren
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

8.  Ganglioside mapping of a human medulloblastoma xenograft.

Authors:  J Gottfries; J E Mansson; P Fredman; C J Wikstrand; H S Friedman; D D Bigner; L Svennerholm
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

9.  Tissue expression of the cancer-associated antigens CA 19-9 and CA-50 in chronic pancreatitis and pancreatic carcinoma.

Authors:  J Schwenk; J Makovitzky
Journal:  Int J Pancreatol       Date:  1989-07

10.  Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.

Authors:  C Haglund; J Lindgren; P J Roberts; S Nordling
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.